Jpmorgan Chase & CO Oncorus, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.24 - $0.76 $228 - $724	-953 Reduced 72.97%	353 $0
Q3 2022 Nov 14, 2022	BUY	$0.85 - $1.65 $263 - $511	310 Added 31.12%	1,306 $1,000
Q2 2022 Aug 11, 2022	SELL	$1.04 - $1.86 $12,056 - $21,562	-11,593 Reduced 92.09%	996 $1,000
Q1 2022 May 11, 2022	SELL	$1.44 - $5.62 $48,376 - $188,803	-33,595 Reduced 72.74%	12,589 $22,000
Q4 2021 Feb 10, 2022	BUY	$5.03 - $11.63 $192,020 - $443,975	38,175 Added 476.65%	46,184 $243,000
Q3 2021 Nov 12, 2021	BUY	$9.29 - $14.27 $74,403 - $114,288	8,009 New	8,009 $75,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.